Ando Therapeutics
- Biotech or pharma, therapeutic R&D
Ando Therapeutics is pioneering an iPSC-derived, allogeneic T cell platform that delivers rejuvenated, immune-evasive CD4+ and CD8+ T cells that can target both surface and intracellular antigens that drive disease.
Our proprietary iPSC-derived CD4+ differentiation process is a breakthrough that enables the generation of CD8+/CD4+ T cell mixes that replicate the functionality of primary T cells— offering the potential to overcome a key challenge in allogeneic CAR-T therapy by restoring both cytotoxic activity and essential regulatory support.
We are developing scalable, off-the-shelf therapies with enhanced efficacy for cancer and autoimmune diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}